| First Author | Hanrahan AJ | Year | 2012 |
| Journal | Cancer Discov | Volume | 2 |
| Issue | 8 | Pages | 666-9 |
| PubMed ID | 22886659 | Mgi Jnum | J:193227 |
| Mgi Id | MGI:5467918 | Doi | 10.1158/2159-8290.CD-12-0308 |
| Citation | Hanrahan AJ, et al. (2012) RAF/MEK dependence of KRAS-mutant pancreatic ductal adenocarcinomas. Cancer Discov 2(8):666-9 |
| abstractText | Studies using genetically engineered mouse models indicate that RAF activation is sufficient to induce pancreatic intraepithelial neoplasms, suggesting that mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor-based combination approaches may have clinical use in patients with pancreatic ductal adenocarcinomas. |
